Valuation: Insmed Incorporated

Market Cap 23.11B 20.25B 18.8B 17.28B 32.56B 2,230B 33.04B 224B 87.67B 1,091B 86.77B 84.9B 3,770B P/E 2026 *
-41.8x
P/E 2027 * 211x
Enterprise Value 22.55B 19.76B 18.34B 16.86B 31.76B 2,176B 32.23B 219B 85.53B 1,065B 84.66B 82.83B 3,678B EV / Sales 2026 *
13.3x
EV / Sales 2027 * 7.97x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day-1.82%
1 week-2.89%
Current month+0.02%
1 month+8.15%
3 months-26.19%
6 months-33.51%
Current year-38.73%
1 week 105.2
Extreme 105.2
110.58
1 month 101.67
Extreme 101.67
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
6/25/26 Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-2.89%+3.61%+405.88% 23.11B
-0.43%-4.26%+52.09%+85.69% 55.27B
+1.95%+3.17%+58.44%+61.62% 54.15B
-0.54%-0.17%-17.60%-15.43% 23.22B
+1.03%-0.20%+36.49%-3.23% 20.33B
-1.77%-0.66%+29.56%-30.29% 17.91B
+0.87%-0.19%+39.07%+553.51% 15.76B
+0.43%-10.61%+175.63%+299.61% 15B
-2.03%-1.03%+23.63%+179.23% 13.82B
-1.67%-2.29%+71.55%+149.20% 12.4B
Average -0.39%-1.72%+47.25%+168.58% 25.1B
Weighted average by Cap. -0.02%-1.11%+45.64%+135.60%

Financials

2026 *2027 *
Net sales 1.7B 1.49B 1.38B 1.27B 2.4B 164B 2.43B 16.48B 6.45B 80.31B 6.38B 6.25B 277B 2.78B 2.43B 2.26B 2.08B 3.91B 268B 3.97B 26.9B 10.53B 131B 10.42B 10.2B 453B
Net income -561M -492M -457M -420M -791M -54.16B -802M -5.44B -2.13B -26.5B -2.11B -2.06B -91.55B 71.64M 62.77M 58.27M 53.55M 101M 6.91B 102M 694M 272M 3.38B 269M 263M 11.68B
Net Debt -563M -493M -458M -421M -793M -54.33B -805M -5.46B -2.14B -26.59B -2.11B -2.07B -91.84B -979M -857M -796M -731M -1.38B -94.43B -1.4B -9.48B -3.71B -46.2B -3.67B -3.59B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-22 US$106.64 -1.82% 1,771,277
26-07-21 US$108.62 +1.50% 2,447,392
26-07-20 US$107.02 -1.20% 2,015,930
26-07-17 US$108.32 +0.80% 2,002,884
26-07-16 US$107.46 -2.14% 2,754,212
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
106.64USD
Average target price
196.18USD
Spread / Average Target
+83.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock